Ivabradine selectively reduces heart rate without affecting blood pressure, contractility, or conduction. The SHIFT trial demonstrated reduced heart failure hospitalization in patients with HFrEF and resting HR >=70 bpm on maximally tolerated beta-blocker therapy. It is the only selective sinus node inhibitor approved for heart failure.
Evidence rating strong. Most-documented uses: reduces heart failure hospitalization (shift trial), selective heart rate reduction without hemodynamic effects, does not reduce blood pressure or contractility. 10 sources indexed (2022–2025), with 3 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Selectively and specifically inhibits the If (funny) current in the sinoatrial node by blocking hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. This slows the rate of diastolic depolarization in pacemaker cells, reducing heart rate without affecting myocardial contractility, blood pressure, or intracardiac conduction. Heart rate reduction is proportional to the baseline rate.3
Ivabradine lowers heart rate and has rare reports of torsades de pointes when other risk factors are present. Low potassium increases torsades risk with bradycardia and QT-risk drugs. Potassium supplements are not routinely needed with ivabradine, but potassium deficiency should be corrected under monitoring.
Recommendation: Keep potassium in the normal range while using ivabradine, especially during diuretic use, gastrointestinal illness, or addition of other QT-prolonging medicines. Do not self-treat with high-dose potassium unless your clinician is checking blood potassium and kidney function. Report fainting, near-fainting, or new sustained palpitations promptly.
Ivabradine can cause clinically important bradycardia, and torsades de pointes has been reported when interacting QT-risk drugs are added. Low magnesium is a recognized torsades risk factor in bradycardic or QT-prolonged states. Magnesium is useful when deficiency is present or likely; it should not be used to mask symptoms such as fainting or severe dizziness.
Recommendation: Maintain normal magnesium intake while taking ivabradine, and ask about checking magnesium if you also use diuretics, proton pump inhibitors, or have chronic diarrhea. Avoid high-dose magnesium without monitoring if you have kidney disease. Seek urgent care for fainting, near-fainting, or sustained palpitations.
St. John's Wort can induce CYP3A4 and P-glycoprotein, and systematic reviews identify ivabradine as a drug whose exposure can be reduced by this herb. Lower ivabradine exposure may reduce heart-rate control and antianginal or heart-failure benefit. The effect can persist after stopping St. John's Wort because enzyme induction takes time to reverse.
Recommendation: Avoid St. John's Wort while taking ivabradine unless your prescriber specifically approves and monitors the combination. Do not use dose spacing as a workaround because this is an enzyme and transporter induction interaction. Tell your clinician if you start or stop St. John's Wort so heart rate, symptoms, and ivabradine dosing can be reassessed.
Kwok CS, Gillespie D, Rehman Qazi NU et al.. Ivabradine as a treatment for postural orthostatic tachycardia syndrome: A systematic review. Journal of cardiovascular pharmacology. 2025
Han J, Wang Q, Jiang L et al.. Efficacy and Safety of Ivabradine for Patients With Acute Heart Failure: Meta-Analysis of Randomized Controlled Trials. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. 2024
Ashraf S, Khalaf AKS, Fatima L et al.. Evaluating the role of ivabradine in acute decompensated heart failure: A systematic review and meta-analysis. Current problems in cardiology. 2024
Sasmita BR, Xie S, Liu G et al.. Ivabradine in patients with acute ST-elevation myocardial infarction: a meta-analysis of randomized controlled trials. The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology. 2023
Wang Z, Wang W, Li H et al.. Ivabradine and Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. Journal of cardiovascular pharmacology. 2022
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Ivabradine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack